21 completed, 1 terminated, 1 withdrawn. 23 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 21, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow fluarix: new trials by email Literature Review of fluarix trials Research Report on fluarix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine - Influenza | Phase 2 | Completed | ModernaTX, Inc. | 172 | 2022-11-02 | 2025-11-24 |
| A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health Ad26.RSV.preF, Fluarix, Placebo - Healthy | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 180 | 2017-12-07 | 2025-02-04 |
| Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Completed | Jennifer Woyach | 42 | 2016-01-12 | 2026-04-06 |
| Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya Quadrivalent Inactivated Influenza Vaccine (QIV), Inactivated Polio Vaccine, Double Dose QIV - Influenza, Human, HIV | Phase 2 / Phase 3 | Withdrawn | Centers for Disease Control and Prevention | 2014-04-01 | 2014-04-10 | |
| Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children GSK Bio's influenza vaccine GSK2584786A, different formulations, GSK Bio's influenza vaccine GSK2321138A, Fluarix™ - Influenza, Influenza Vaccines | Phase 2 | Terminated | GlaxoSmithKline | 4 | 2010-09-30 | 2020-10-30 |
| FluMist in Egg Allergic Patients FluMist intranasal influenza vaccine, Intramuscular influenza injection ("flu shot") - Egg Allergy, Eligible for Vaccination Against Influenza | Phase 1 / Phase 2 | Completed | Walter Reed Army Medical Center | 17 | 2010-09-01 | 2018-10-03 |
| Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children Influenza vaccine GSK2321138A, Fluarix™ - Influenza | Phase 2 | Completed | GlaxoSmithKline | 599 | 2009-10-08 | 2018-09-21 |
| Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly Pandemrix (Influenza vaccine GSK2340272A), Fluarix™, Placebo - Influenza | Phase 2 | Completed | GlaxoSmithKline | 168 | 2009-09-12 | 2018-08-20 |
| Influenza Vaccine in Pregnant Women Fluzone®, Fluarix® - Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 102 | 2009-06-01 | 2012-06-13 |
| Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults GSK Biologicals' influenza vaccine GSK576389A, Fluarix™ - Influenza | Phase 2 | Completed | GlaxoSmithKline | 68 | 2007-10-23 | 2018-06-08 |
| Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults Fluarix™, GSK Bio's Influenza Vaccine GSK576389A - Influenza | Phase 2 | Completed | GlaxoSmithKline | 133 | 2007-10-15 | 2018-06-08 |
| Revaccination With Influenza Vaccine GSK1247446A Influenza Vaccine GSK1247446A, Fluarix™ - Influenza, Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 243 | 2007-10-15 | 2019-06-26 |
| Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A GlaxoSmithKline Biologicals' influenza vaccine GSK576389A, Fluarix - Influenza | Phase 2 | Completed | GlaxoSmithKline | 2007 | 2007-10-08 | 2018-06-08 |
| Study to Evaluate an Influenza Vaccine Candidate Influenza Vaccine GSK1247446A - 4 different formulations, Fluarix™ - Influenza | Phase 2 | Completed | GlaxoSmithKline | 1006 | 2007-10-05 | 2019-06-14 |
| Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season], GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season], Fluarix [NH 2006/07 season] - Influenza | Phase 2 | Completed | GlaxoSmithKline | 1596 | 2007-09-20 | 2018-06-08 |
| Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Pandemic Influenza Vaccine (GSK1562902A), Fluarix™ - Influenza | Phase 2 | Completed | GlaxoSmithKline | 138 | 2007-07-23 | 2018-10-25 |
| Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix - Influenza | Phase 2 | Completed | GlaxoSmithKline | 437 | 2006-11-17 | 2019-06-10 |
| Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Fluarix and adjuvanted influenza vaccine - Influenza | Phase 2 | Completed | GlaxoSmithKline | 74 | 2006-10-16 | 2018-02-26 |
| Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate Fluarix™, GSK1247446A - Influenza | Phase 2 | Completed | GlaxoSmithKline | 300 | 2006-10-03 | 2018-06-08 |
| Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate GSK1247446A Group, Fluarix™ - Influenza | Phase 2 | Completed | GlaxoSmithKline | 150 | 2006-10-02 | 2018-06-08 |
Showing 20 of 23. Sign in to see all of them.
Influenza, Human (21) · Egg Hypersensitivity (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Malaria (1) · Poliomyelitis (1) · Tetanus (1)
GlaxoSmithKline (17) · Centers for Disease Control and Prevention (1) · Janssen Vaccines & Prevention B.V. (1) · Jennifer Woyach (1) · ModernaTX, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Walter Reed Army Medical Center (1)
Belgium (10) · United States (6) · Germany (3) · Spain (3) · Norway (2) · Sweden (2) · Denmark (1) · Estonia (1) · France (1) · Italy (1) · Kenya (1) · Mexico (1) · Netherlands (1) · United Kingdom (1)
Jennifer Woyach, MD (1) · Joshua A Mott, PhD (1) · Marc-Alain Widdowson, VetMB, MSc (1) · Meredith L McMorrow, MD, MPH (1) · Nancy Otieno, MS (1) · Susan Laubach, MD (1)
PMID 20375709, PMID 22885014, PMID 23890405, PMID 25386965, PMID 25652873, PMID 32851411, PMID 34608724